Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Genes, chromosomes & cancer. 2015 Sep 10. doi: 10.1002/gcc.22292
    Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.
    Braulke F1,  Müller-Thomas C2,  Götze K3,  Platzbecker U4,  Germing U5,  Hofmann WK6,  Giagounidis AA7,  Lübbert M8,  Greenberg PL9,  Bennett JM10,  Solé F11,  Slovak ML12,  Ohyashiki K13,  Le Beau MM14,  Tüchler H15,  Pfeilstöcker M16,  Hildebrandt B17,  Aul C18,  Stauder R19,  Valent P20,  Fonatsch C21,  Bacher U22,  Trümper L23,  Haase D24,  Schanz J25
    Author information
    1Department of Hematology and Medical Oncology, University Medicine of Goettingen, Germany.
    2Department of Hematology and Oncology, Technical University of Munich, Germany.
    3Department of Hematology and Oncology, Technical University of Munich, Germany.
    4Department of Hematology and Oncology, University of Dresden, Germany.
    5Department of Hematology and Oncology, University of Duesseldorf, Germany.
    6Department of Hematology and Oncology, University Hospital of Mannheim, Germany.
    7Department of Hematology and Oncology, Marienhospital, Duesseldorf, Germany.
    8Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany.
    9Department of Hematology, Stanford University Cancer Center, Stanford, CA.
    10University of Rochester Medical Center, Rochester, NY.
    11Institut De Recerca Contra La Leukemia Josep Carreras, Badalona, Spain.
    12Sonora Quest Laboratories, Phoenix, AZ.
    13Tokyo Medical University, Tokyo, Japan.
    14Section of Hematology and Oncology, University of Chicago, Chicago, IL.
    15Hanusch Hospital Boltzmann Institute for Leukemia Research, Vienna, Austria.
    16Third Medical Department for Hematology and Oncology and L. Boltzmann Cluster Oncology, Hanusch Hospital, Vienna, Austria.
    17Department of Human Genetics, University of Düsseldorf, Düsseldorf, Germany.
    18Department of Hematology, Oncology and Clinical Immunology, St. Johannes Hospital, Duisburg, Germany.
    19Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria.
    20Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
    21Department of Medical Genetics, Medical University of Vienna, Vienna, Austria.
    22Department of Hematology and Medical Oncology, University Medicine of Goettingen, Germany.
    23Department of Hematology and Medical Oncology, University Medicine of Goettingen, Germany.
    24Department of Hematology and Medical Oncology, University Medicine of Goettingen, Germany.
    25Department of Hematology and Medical Oncology, University Medicine of Goettingen, Germany.
    Abstract

    In myelodysplastic syndromes (MDS), deletion of the short arm of chromosome 12 (del(12p)) is usually a small abnormality, rarely detected as a single aberration by chromosome banding analysis (CBA) of bone marrow metaphases. Del(12p) has been described in 0.6 to 5% of MDS patients at initial diagnosis and is associated with a good to intermediate prognosis as a sole anomaly according to current scoring systems. Here, we present the results of a systematic del(12p) testing in a German prospective diagnostic study (clinicaltrials.gov: NCT01355913) on 367 MDS patients in whom CD34+ peripheral blood cells were analysed for the presence of del(12p) by sequential fluorescence in situ hybridization (FISH) analyses. A cohort of 2,902 previously published MDS patients diagnosed by CBA served as control. We demonstrate that, using a sensitive FISH technique, 12p deletion occurs significantly more frequently in MDS than previously described (7.6% by CD34+ PB-FISH vs. 1.6% by CBA, P < 0.001) and is often associated with other aberrations (93% by CD34+ PB-FISH vs. 60% by CBA). Additionally, the detection rate can be increased by repeated analyses in a patient over time which is important for the patient´s prognosis to distinguish a sole anomaly from double or complex aberrations. To our knowledge, this is the first study to screen for 12p deletions with a suitable probe for ETV6/TEL in 12p13. Our data suggest that the supplement of a probe for the detection of a 12p deletion to common FISH probe panels helps to avoid missing a del(12p), especially as part of more complex aberrations.


    © 2015 Wiley Periodicals, Inc.

    Publikations ID: 26355708
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt